Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Alzheimer’s disease
Tau aggregation inhibitor
acetylcholinesterase
inhibitor (AChEI)
drug interaction
hydromethylthionine
mouse model
synaptic proteins
tauopathy.
Journal
Current Alzheimer research
ISSN: 1875-5828
Titre abrégé: Curr Alzheimer Res
Pays: United Arab Emirates
ID NLM: 101208441
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
08
2019
revised:
08
01
2020
accepted:
12
02
2020
pubmed:
25
2
2020
medline:
25
5
2021
entrez:
25
2
2020
Statut:
ppublish
Résumé
Symptomatic treatments of Alzheimer's Disease (AD) with cholinesterase inhibitors and/or memantine are relatively ineffective and there is a need for new treatments targeting the underlying pathology of AD. In most of the failed disease-modifying trials, patients have been allowed to continue taking symptomatic treatments at stable doses, under the assumption that they do not impair efficacy. In recently completed Phase 3 trials testing the tau aggregation inhibitor leuco-methylthioninium bis (hydromethanesulfonate) (LMTM), we found significant differences in treatment response according to whether patients were taking LMTM either as monotherapy or as an add-on to symptomatic treatments. We have examined the effect of either LMTM alone or chronic rivastigmine prior to LMTM treatment of tau transgenic mice expressing the short tau fragment that constitutes the tangle filaments of AD. We have measured acetylcholine levels, synaptosomal glutamate release, synaptic proteins, mitochondrial complex IV activity, tau pathology and Choline Acetyltransferase (ChAT) immunoreactivity. LMTM given alone increased hippocampal Acetylcholine (ACh) levels, glutamate release from synaptosomal preparations, synaptophysin levels in multiple brain regions and mitochondrial complex IV activity, reduced tau pathology, partially restored ChAT immunoreactivity in the basal forebrain and reversed deficits in spatial learning. Chronic pretreatment with rivastigmine was found to reduce or eliminate almost all these effects, apart from a reduction in tau aggregation pathology. LMTM effects on hippocampal ACh and synaptophysin levels were also reduced in wild-type mice. The interference with the pharmacological activity of LMTM by a cholinesterase inhibitor can be reproduced in a tau transgenic mouse model and, to a lesser extent, in wild-type mice. Long-term pretreatment with a symptomatic drug alters a broad range of brain responses to LMTM across different transmitter systems and cellular compartments at multiple levels of brain function. There is, therefore, no single locus for the negative interaction. Rather, the chronic neuronal activation induced by reducing cholinesterase function produces compensatory homeostatic downregulation in multiple neuronal systems. This reduces a broad range of treatment responses to LMTM associated with a reduction in tau aggregation pathology. Since the interference is dictated by homeostatic responses to prior symptomatic treatment, it is likely that there would be similar interference with other drugs tested as add-on to the existing symptomatic treatment, regardless of the intended therapeutic target or mode of action. The present findings outline key results that now provide a working model to explain interference by symptomatic treatment.
Sections du résumé
BACKGROUND
Symptomatic treatments of Alzheimer's Disease (AD) with cholinesterase inhibitors and/or memantine are relatively ineffective and there is a need for new treatments targeting the underlying pathology of AD. In most of the failed disease-modifying trials, patients have been allowed to continue taking symptomatic treatments at stable doses, under the assumption that they do not impair efficacy. In recently completed Phase 3 trials testing the tau aggregation inhibitor leuco-methylthioninium bis (hydromethanesulfonate) (LMTM), we found significant differences in treatment response according to whether patients were taking LMTM either as monotherapy or as an add-on to symptomatic treatments.
METHODS
We have examined the effect of either LMTM alone or chronic rivastigmine prior to LMTM treatment of tau transgenic mice expressing the short tau fragment that constitutes the tangle filaments of AD. We have measured acetylcholine levels, synaptosomal glutamate release, synaptic proteins, mitochondrial complex IV activity, tau pathology and Choline Acetyltransferase (ChAT) immunoreactivity.
RESULTS
LMTM given alone increased hippocampal Acetylcholine (ACh) levels, glutamate release from synaptosomal preparations, synaptophysin levels in multiple brain regions and mitochondrial complex IV activity, reduced tau pathology, partially restored ChAT immunoreactivity in the basal forebrain and reversed deficits in spatial learning. Chronic pretreatment with rivastigmine was found to reduce or eliminate almost all these effects, apart from a reduction in tau aggregation pathology. LMTM effects on hippocampal ACh and synaptophysin levels were also reduced in wild-type mice.
CONCLUSION
The interference with the pharmacological activity of LMTM by a cholinesterase inhibitor can be reproduced in a tau transgenic mouse model and, to a lesser extent, in wild-type mice. Long-term pretreatment with a symptomatic drug alters a broad range of brain responses to LMTM across different transmitter systems and cellular compartments at multiple levels of brain function. There is, therefore, no single locus for the negative interaction. Rather, the chronic neuronal activation induced by reducing cholinesterase function produces compensatory homeostatic downregulation in multiple neuronal systems. This reduces a broad range of treatment responses to LMTM associated with a reduction in tau aggregation pathology. Since the interference is dictated by homeostatic responses to prior symptomatic treatment, it is likely that there would be similar interference with other drugs tested as add-on to the existing symptomatic treatment, regardless of the intended therapeutic target or mode of action. The present findings outline key results that now provide a working model to explain interference by symptomatic treatment.
Identifiants
pubmed: 32091331
pii: CAR-EPUB-104783
doi: 10.2174/1567205017666200224120926
pmc: PMC7403648
doi:
Substances chimiques
Cholinesterase Inhibitors
0
MAPT protein, human
0
Protein Aggregates
0
tau Proteins
0
hydromethylthionine
IHU4GYZ2R3
Rivastigmine
PKI06M3IW0
Methylene Blue
T42P99266K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-296Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Brain Res. 2017 Sep 1;1670:173-184
pubmed: 28652219
Anat Rec. 1946 Feb;94:239-47
pubmed: 21015608
Behav Neurosci. 2007 Apr;121(2):264-76
pubmed: 17469916
J Mol Biol. 2018 Oct 19;430(21):4119-4131
pubmed: 30121297
Neuropsychopharmacology. 2012 Mar;37(4):1057-66
pubmed: 22129780
FEBS Lett. 2019 Mar;593(5):499-503
pubmed: 30734287
J Comp Neurol. 2013 Dec 15;521(18):4124-44
pubmed: 23852922
Ann Intern Med. 2008 Mar 4;148(5):379-97
pubmed: 18316756
Hum Mol Genet. 2014 Jul 15;23(14):3716-32
pubmed: 24556215
J Alzheimers Dis. 2018;66(2):425-427
pubmed: 30282371
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8
pubmed: 8855335
Psychopharmacology (Berl). 2009 Jan;202(1-3):53-65
pubmed: 19005644
Nat Rev Neurosci. 2018 Jan 19;19(2):63-80
pubmed: 29348666
J Alzheimers Dis. 2018;61(1):435-457
pubmed: 29154277
Ther Adv Neurol Disord. 2009 May;2(3):163-80
pubmed: 21179526
Mol Med Rep. 2016 Jan;13(1):13-20
pubmed: 26572258
Nature. 2017 Jul 13;547(7662):185-190
pubmed: 28678775
Lancet. 2004 Jun 26;363(9427):2105-15
pubmed: 15220031
Lancet. 2016 Dec 10;388(10062):2873-2884
pubmed: 27863809
Front Mol Neurosci. 2018 Jan 10;10:447
pubmed: 29375308
J Alzheimers Dis. 2018;62(3):1287-1303
pubmed: 29226873
J Psychiatry Neurosci. 2013 Jan;38(1):6-23
pubmed: 22894822
J Pharmacol Exp Ther. 2015 Jan;352(1):110-8
pubmed: 25320049
Alzheimers Res Ther. 2014 Jul 03;6(4):37
pubmed: 25024750
BMJ Open. 2013 Jan 07;3(1):
pubmed: 23299113
Br J Pharmacol. 1997 Sep;122(1):95-8
pubmed: 9298533
J Manag Care Pharm. 2005 Apr;11(3):231-51
pubmed: 15804207
J Am Geriatr Soc. 2005 Jul;53(7):1269-70
pubmed: 16108961
Arch Neurol. 2011 Jan;68(1):58-66
pubmed: 21220675
Neural Regen Res. 2018 Apr;13(4):616-623
pubmed: 29722304
Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3247-3256
pubmed: 30006151
Behav Brain Res. 2011 Aug 10;221(2):443-65
pubmed: 21315109
Nat Rev Neurol. 2019 Feb;15(2):73-88
pubmed: 30610216
Neurobiol Aging. 2002 Jul-Aug;23(4):601-13
pubmed: 12009509
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4506-10
pubmed: 3132715
Cell Mol Life Sci. 2015 Jun;72(11):2199-222
pubmed: 25523019
ACS Chem Neurosci. 2019 Apr 17;10(4):1915-1922
pubmed: 30253092
Psychol Sci. 2008 Nov;19(11):1185-93
pubmed: 19076492
FASEB J. 2008 Mar;22(3):703-12
pubmed: 17928358
J Physiol Paris. 2016 Sep;110(1-2):10-18
pubmed: 27404793
Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50
pubmed: 20398692
Biofactors. 2012 Mar-Apr;38(2):158-66
pubmed: 22419586
Autophagy. 2012 Apr;8(4):609-22
pubmed: 22361619
Psychopharmacology (Berl). 2018 Apr;235(4):1093-1105
pubmed: 29332255
Behav Pharmacol. 2015 Jun;26(4):353-68
pubmed: 25769090
J Am Geriatr Soc. 2016 Aug;64(8):1540-8
pubmed: 27341454
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
J Biol Chem. 2015 Apr 24;290(17):10862-75
pubmed: 25759392
Neurobiol Aging. 2011 Dec;32(12):2325.e7-16
pubmed: 21316815
Biochem Pharmacol. 2009 Oct 15;78(8):927-32
pubmed: 19433072
Proc Natl Acad Sci U S A. 1988 Jul;85(13):4884-8
pubmed: 2455299
J Alzheimers Dis. 2019;72(3):931-946
pubmed: 31658058